New Coronavirus Tests Have These Diagnostics Companies Recalibrating

It took almost two months before the Food and Drug Administration and the Centers for Disease Control were able to remedy some of those problems and private COVID-19 tests began to reach the American public. From there, several companies helped lead the charge to make tests widely available, and their stocks skyrocketed as a result. Shares of OPKO Health (NASDAQ: OPK) and Quidel (NASDAQ: QDEL) benefited the most, up 217 % and 161% year to date, respectively.